Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").

Authors not listed

Quark Pharmaceuticals · 2007

Abstract

The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2007). A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD"). <em>Quark Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT00725686
Vancouver
Anonymous. A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD"). Quark Pharmaceuticals. 2007.
BibTeX
@misc{anon2007APhase, title = {A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").}, author = {Anonymous}, journal = {Quark Pharmaceuticals}, year = {2007}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings